This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis

This study has been terminated.
(Study had completed enrollment but drug injection was halted due to an unacceptable incidence of rash.)
Information provided by (Responsible Party):
Genentech, Inc. Identifier:
First received: July 16, 2008
Last updated: March 6, 2012
Last verified: March 2012
This is a Phase I multicenter study that will be conducted in the United States and consists of a double-blind, placebo-controlled, SAD stage, followed by a double-blind, placebo controlled MAD stage. The study will be conducted in approximately 65 adult patients between 18 and 80 years old who have RA.

Condition Intervention Phase
Rheumatoid Arthritis Drug: MTRX1011A Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial, With a Single Ascending-Dose Stage Followed by a Multiple Ascending-Dose Stage, of the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous MTRX1011A in Patients With Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by Genentech, Inc.:

Primary Outcome Measures:
  • Safety and tolerability of MTRX1011A in both the SAD and MAD stages [ Time Frame: Length of study ]

Secondary Outcome Measures:
  • Characterize the pharmacokinetic response of MTRX1011A [ Time Frame: Length of study ]
  • Characterize the pharmacodynamic profile of single and multiple doses of MTRX1011A [ Time Frame: Length of study ]

Enrollment: 66
Study Start Date: July 2008
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: MTRX1011A
    Subcutaneous and intravenous single and repeating dose

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. SAD Stage

    • RA diagnosed according to the ACR
    • For patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization
    • Previous treatment with biologic agents, including anti-TNF agents, permitted but discontinued for an appropriate washout period
  2. MAD Stage (same as above with the addition of the following)

    • Failure of at least one biologic agent, defined as lack of or loss of response or intolerance
    • Active disease defined by swollen and tender count

Exclusion Criteria:

  • Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome
  • Malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected
  • History of treatment with any T cell-directed therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00718588

Sponsors and Collaborators
Genentech, Inc.
Study Director: John Davis, M.D., M.P.H. Genentech, Inc.
  More Information

Responsible Party: Genentech, Inc. Identifier: NCT00718588     History of Changes
Other Study ID Numbers: CDT4478g
Study First Received: July 16, 2008
Last Updated: March 6, 2012

Keywords provided by Genentech, Inc.:

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 21, 2017